COMPANY NEWS - NEWS - 海森生物

News & Events

PRESS RELEASE

Scroll down

News & Events

WITNESSING OUR DEVELOPMENT

COMPANY NEWS

Hasten's 3^rd Partner Exchange Conference was Successfully Held in Shenzhen

2024-10-29

On September 24, 2024, the 3rd Partner Exchange Conference hosted by Hasten Biopharmaceutical Co., Ltd. was grandly held in Shenzhen, Guangdong.

FIND OUT MORE

2024-09-26

Hasten and China Resources (Shanghai) Signed a Strategic Agreement to Deepen the Comprehensive Collaboration

On Sept. 24, 2024, Hasten Biopharmaceutical Co., Ltd. and China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. signed a strategic agreement to deepen the comprehensive collaboration on further increasing branded drugs’ accessibility to Chinese patients.
FIND OUT MORE
2024-09-12

Based on Asia-Pacific, Winning Together丨Representatives of Celltrion Visited Hasten Shanghai

On September 6th, 2024, representatives from Celltrion, a Korean biopharmaceutical company, visited the Shanghai Operations Management Center of Hasten Biopharmaceutical Co.,Ltd (referred to as “Hasten”).
FIND OUT MORE
2024-06-28

Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area

[June 28th, 2024] Hasten Biopharmaceutical Co., Ltd. (referred to as “Hasten”) announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company.
FIND OUT MORE
2024-05-24

Hasten Announced that the Clinical Trial Application for Lerodalcibep has been Approved by the National Medical Products Administration's CDE

On May. 17th, 2024, Hasten Biopharmaceutical Limited Co., Ltd. (hereinafter as Hasten) announced that the clinical trial application (IND) for Lerodalcibep(hereinafter as the code：HST101), a novel third-generation PCSK9 inhibitor, has been approved by the Center for Drug Evaluation(CDE) of the National Medical Products Administration (NMPA) for the treatment of patients with hypercholesterolemia. The Company will accelerate domestic clinical trial preparations and initiate recruitment of subjects with hypercholesterolaemia.
FIND OUT MORE
2024-04-01

Hasten and Naxions Signed a Strategic Cooperation Agreement on the "Hasten&Naxions Innovation Project"

On 29th, March, Hasten Biopharmaceutical Co., Ltd (hereinafter referred to as "Hasten") signed a strategic cooperation agreement with Naxions on the "Hasten&Naxions Innovation Project". According to the agreement, Naxions will assist in promoting the accessibility of Hasten's high-quality products in specific markets through its multi-dimensional digital model to benefit more patients and jointly create greater social health value.
FIND OUT MORE
2023-12-25

Hasten Signed MOU with CR Gosun for Deep Collaboration

On December 19, 2023, Hasten’s CEO Summer XIA, Vice President and Head of Commercial Excellence Hanson Zheng and other senior leaders from Hasten visited Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun), and signed a MOU for the deep collaboration with CR Gosun.
FIND OUT MORE

<1 2 3 4 >

HEFEI BEIJING SHANGHAI GUANGZHOU HANGZHOU

No.99, Shanshui Road, Dianbu Town, Feidong County, Hefei, Anhui, China

Eberson Pharmaceuticals Co., Ltd.

No.69, Shanshui Road, Dianbu Town, Feidong County, Hefei, Anhui, China

601-603/6F, Fortune Financial Center 5 Dong San Huan Central Road Chaoyang District, Beijing, China

22nd Floor, New Bund Shun Tak Center No. 18, Lane 666, Hai Yang West Road, Pudong New Area, SHANGHAI 200026

Room 3301-3302, China International Center Tower B, No. 33 Zhongshan Third Road Yuexiu, Guangzhou, China

20th Floor, #G Build, Huanglong International Center Tower, No.77, Xueyuan Road, West Lake District, Hangzhou, Zhejiang, China

Guidelines for Reporting Adverse Drug Reactions

HONG KONG

GERMANY

BEIJING

SHANGHAI

SWITZERLAND

HEFEI

GUANGZHOU

Disclaimer | Privacy | Terms of Use